Domestic drugs accounted for 62% of packages of antitumor drugs in Russia
The share of Russian anticancer drugs in the market amounted to 62% in the first nine months of 2026, follows from the data of the Center for the Development of Advanced Technologies (CRPT) – the operator of the labeling system “Honest Sign”. This is in line with 2021 levels, although the country has since advanced in the production of a number of critical molecules, such as hydroxycarbamide.
The share of Russian anticancer drugs in the market amounted to 62% in the first nine months of 2026, follows from the data of the Center for the Development of Advanced Technologies (CRPT) – the operator of the labeling system “Honest Sign”. This is in line with 2021 levels, although the country has since advanced in the production of a number of critical molecules, such as hydroxycarbamide.
